^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

Published date:
12/06/2020
Excerpt:
112 patients with relapsed or refractory AML had received vibecotamab....Biomarker analyses suggest that low baseline leukemic burden and low PD-1 expression on CD4+ and CD8+ T cells are independent predictors of response...The overall response rate (ORR) was 15% (n=8/54)...